In Pancreatic Cancer, Blood Neutrophil-Lymphocyte Ratio Predicts Survival

Share this content:

the Cancer Therapy Advisor take:

Baseline and post-chemotherapy neutrophil-lymphocyte ratio (NLR) change are potential biomarkers for overall survival in patients with advanced pancreatic cancer undergoing chemotherapy, according to a study published in the Annals of Surgical Oncology.

Researchers at the Fudan University Shanghai Cancer Center in China retrospectively examined 403 patients who had undergone chemotherapy for advanced pancreatic adenocarcinoma from 2002 to 2013. They wanted to determine the prognostic role of NLR in these patients.

The researchers performed univariate and multivariate analyses in order to identify clinicopathological predictors of overall survival that included baseline NLR and post-chemotherapy NLR.

They found that both baseline NLR and post-chemotherapy NLR change were independent prognostic factors in overall survival.

NLR of 3.1 or greater before chemotherapy as well as NLR post-chemotherapy change were both significantly associated with distant metastasis, serum CA19-9 levels and serum albumin levels.

New advances regarding treatment options for metastatic pancreatic cancer.
NLR change is a potential biomarker for survival in advanced pancreatic cancer.
This study assessed the prognostic role of neutrophil–to–lymphocyte ratio (NLR) in patients with advanced pancreatic cancer undergoing chemotherapy. The researchers concluded that baseline NLR and post–chemotherapy NLR changes may serve as potential biomarkers for overall survival in these patients.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs